Pradaxa gets stroke prevention nod in the EU
This article was originally published in Scrip
Executive Summary
The EU's CHMP has granted a positive opinion for Boehringer Ingelheim's direct thrombin inhibitor Pradaxa (dabigatran etexilate) to add the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation to its label.